Citations (153)
Keep up to date with the latest research on this topic with citation updates for this article.
Read on this site (6)
Sue Haupt, Catherine Mitchell, Vincent Corneille, Jake Shortt, Stephen Fox, Pier Paolo Pandolfi, Mireia Castillo-Martin, Dennis Bonal, Carlos Cordon-Carlo, Guillermina Lozano & Ygal Haupt. (2013) Loss of PML cooperates with mutant p53 to drive more aggressive cancers in a gender-dependent manner. Cell Cycle 12:11, pages 1722-1731.
Read now
Read now
Timo Quante, Benjamin Otto, Marie Brázdová, Iva Kejnovská, Wolfgang Deppert & Genrich V. Tolstonog. (2012) Mutant p53 is a transcriptional co-factor that binds to G-rich regulatory regions of active genes and generates transcriptional plasticity. Cell Cycle 11:17, pages 3290-3303.
Read now
Read now
Eyal Kalo, Yosef Buganim, Keren E. Shapira, Hilla Besserglick, Naomi Goldfinger, Lilach Weisz, Perry Stambolsky, Yoav I. Henis & Varda Rotter. (2007) Mutant p53 Attenuates the SMAD-Dependent Transforming Growth Factor β1 (TGF-β1) Signaling Pathway by Repressing the Expression of TGF-β Receptor Type II. Molecular and Cellular Biology 27:23, pages 8228-8242.
Read now
Read now
Mariano J. Scian, Katherine E. R. Stagliano, Michelle A. E. Anderson, Sajida Hassan, Melissa Bowman, Mike F. Miles, Swati Palit Deb & Sumitra Deb. (2005) Tumor-Derived p53 Mutants Induce NF-κB2 Gene Expression. Molecular and Cellular Biology 25:22, pages 10097-10110.
Read now
Read now
Yoichi Ohiro, Anny Usheva, Shinichiro Kobayashi, Shannon L. Duffy, Regan Nantz, David Gius & Nobuo Horikoshi. (2003) Inhibition of Stress-Inducible Kinase Pathways by Tumorigenic Mutant p53. Molecular and Cellular Biology 23:1, pages 322-334.
Read now
Read now
Charles J. Di Como, Christian Gaiddon & Carol Prives. (1999) p73 Function Is Inhibited by Tumor-Derived p53 Mutants in Mammalian Cells. Molecular and Cellular Biology 19:2, pages 1438-1449.
Read now
Read now
Articles from other publishers (147)
Dhana Sekaran Ganesan, Dhasarathan Annadurai, Lakshmanan Vadakkuvaselvi, Kathirvel Neelan & Arulvasu Chinnasamy. (2022) Antitumor effect of partially purified venom protein from Conus virgo on rat glioma cell line. The Journal of Basic and Applied Zoology 83:1.
Crossref
Crossref
Xiaoyi Lin, Xin Lin, Lijuan Guo, Yulei Wang & Guochun Zhang. (2022)
Distinct clinicopathological characteristics, genomic alteration and prognosis in breast cancer with concurrent
TP53
mutation and
MYC
amplification
. Thoracic Cancer 13:24, pages 3441-3450.
Crossref
Crossref
Maria Anele Romeo, Maria Saveria Gilardini Montani, Andrea Arena, Rossella Benedetti, Gabriella D’Orazi & Mara Cirone. (2022) c-Myc Sustains Pancreatic Cancer Cell Survival and mutp53 Stability through the Mevalonate Pathway. Biomedicines 10:10, pages 2489.
Crossref
Crossref
Sufeng Zhao, Li An, Xudong Yang, Zheng Wei, He Zhang & Yufeng Wang. (2022) Identification and validation of the role of c-Myc in head and neck squamous cell carcinoma. Frontiers in Oncology 12.
Crossref
Crossref
Liz J. Hernández Borrero & Wafik S. El-Deiry. (2021) Tumor suppressor p53: Biology, signaling pathways, and therapeutic targeting. Biochimica et Biophysica Acta (BBA) - Reviews on Cancer 1876:1, pages 188556.
Crossref
Crossref
J. P. Jose Merlin, H. P. Vasantha Rupasinghe, Graham Dellaire & Kieran Murphy. (2021) Role of Dietary Antioxidants in p53-Mediated Cancer Chemoprevention and Tumor Suppression. Oxidative Medicine and Cellular Longevity 2021, pages 1-18.
Crossref
Crossref
Petra Grbčić, Dora Fučkar Čupić, Tania Gamberi, Sandra Kraljević Pavelić & Mirela Sedić. (2021) Proteomic Profiling of BRAFV600E Mutant Colon Cancer Cells Reveals the Involvement of Nucleophosmin/c-Myc Axis in Modulating the Response and Resistance to BRAF Inhibition by Vemurafenib. International Journal of Molecular Sciences 22:12, pages 6174.
Crossref
Crossref
Robbin Nameki, Heidi Chang, Jessica Reddy, Rosario I. Corona & Kate Lawrenson. (2021) Transcription factors in epithelial ovarian cancer: histotype-specific drivers and novel therapeutic targets. Pharmacology & Therapeutics 220, pages 107722.
Crossref
Crossref
Amit Jangid, Md. Zubbair Malik, Ram Ramaswamy & R. K. Brojen Singh. (2021) Transition and identification of pathological states in p53 dynamics for therapeutic intervention. Scientific Reports 11:1.
Crossref
Crossref
Dishari Ghatak, Damayanti Das Ghosh & Susanta Roychoudhury. (2021) Cancer Stemness: p53 at the Wheel. Frontiers in Oncology 10.
Crossref
Crossref
Arutselvan Natarajan, Husam A. Babikir, Ramasamy Paulmurugan & Tarik F. Massoud. 2021. Glioblastoma Resistance to Chemotherapy: Molecular Mechanisms and Innovative Reversal Strategies. Glioblastoma Resistance to Chemotherapy: Molecular Mechanisms and Innovative Reversal Strategies
749
771
.
David A. Sallman, Amy F. McLemore, Amy L. AldrichRami S. Komrokji, Kathy L. McGrawAbhishek DhawanSusan GeyerHsin-An HouErika A. EksiogluAmy SullivanSarah WarrenKyle J. MacBethManja MeggendorferTorsten HaferlachSteffen Boettcher, Benjamin L. Ebert, Najla H. Al AliJeffrey E. LancetJohn L. Cleveland, Eric PadronAlan F. List. (2020)
TP53
mutations in myelodysplastic syndromes and secondary AML confer an immunosuppressive phenotype
. Blood 136:24, pages 2812-2823.
Crossref
Crossref
Federica Ganci, Claudio Pulito, Sara Valsoni, Andrea Sacconi, Chiara Turco, Mahrou Vahabi, Valentina Manciocco, Emilia Maria Cristina Mazza, Jalna Meens, Christina Karamboulas, Anthony C. Nichols, Renato Covello, Raul Pellini, Giuseppe Spriano, Giuseppe Sanguineti, Paola Muti, Silvio Bicciato, Laurie Ailles, Sabrina Strano, Giulia Fontemaggi & Giovanni Blandino. (2020) PI3K Inhibitors Curtail MYC-Dependent Mutant p53 Gain-of-Function in Head and Neck Squamous Cell Carcinoma. Clinical Cancer Research 26:12, pages 2956-2971.
Crossref
Crossref
Xuanwen Bao, Run Shi, Tianyu Zhao & Yanfang Wang. (2020) Mast cell‐based molecular subtypes and signature associated with clinical outcome in early‐stage lung adenocarcinoma. Molecular Oncology 14:5, pages 917-932.
Crossref
Crossref
Eduardo Henrique Neves Filho, Carlos Gustavo Hirth, Igor Allen Frederico, Rommel Mario Burbano, Thiago Carneiro & Silvia Helena Rabenhorst. (2020) EZH2 expression is dependent on MYC and TP53 regulation in diffuse large B‐cell lymphoma. APMIS 128:4, pages 308-315.
Crossref
Crossref
Hyun-Jung Moon, So-Young Park, Su-Hoon Lee, Chi-Dug Kang & Sun-Hee Kim. (2019) Nonsteroidal Anti-inflammatory Drugs Sensitize CD44-Overexpressing Cancer Cells to Hsp90 Inhibitor Through Autophagy Activation. Oncology Research Featuring Preclinical and Clinical Cancer Therapeutics 27:7, pages 835-847.
Crossref
Crossref
Xiang Zhou, Qian Hao & Hua Lu. (2019) Mutant p53 in cancer therapy—the barrier or the path. Journal of Molecular Cell Biology 11:4, pages 293-305.
Crossref
Crossref
Ya-Chen Ko, Chung-Yi Hu, Zheng-Hau Liu, Hwei-Fang Tien, Da-Liang Ou, Hsiung-Fei Chien & Liang-In Lin. (2019) Cytarabine-Resistant FLT3-ITD Leukemia Cells are Associated with TP53 Mutation and Multiple Pathway Alterations—Possible Therapeutic Efficacy of Cabozantinib. International Journal of Molecular Sciences 20:5, pages 1230.
Crossref
Crossref
Seitaro NAKAZAWA, Ken-ichiro SAKATA, Shanshan LIANG, Kazuhito YOSHIKAWA, Hisashi IIZASA, Mitsuhiro TADA, Jun-ichi HAMADA, Haruhiko KASHIWAZAKI, Yoshimasa KITAGAWA & Yutaka YAMAZAKI. (2019) <b>Dominant-negative p53 mutant R248Q increases the motile and invasive activities of oral squamous cell carcinoma</b><b> cells </b>. Biomedical Research 40:1, pages 37-49.
Crossref
Crossref
Husam A. Babikir, Rayhaneh Afjei, Ramasamy Paulmurugan & Tarik F. Massoud. (2018) Restoring guardianship of the genome: Anticancer drug strategies to reverse oncogenic mutant p53 misfolding. Cancer Treatment Reviews 71, pages 19-31.
Crossref
Crossref
Parijat Senapati, Suchismita Dey, Deepthi Sudarshan, Sadhan Das, Manoj Kumar, Stephanie Kaypee, Azeem Mohiyuddin, Gopinath S. Kodaganur & Tapas K. Kundu. (2018) Oncogene c‐fos and mutant R175H p53 regulate expression of Nucleophosmin implicating cancer manifestation. The FEBS Journal 285:18, pages 3503-3524.
Crossref
Crossref
Ana Sara Gomes, Helena Ramos, Joana Soares & Lucília Saraiva. (2018) p53 and glucose metabolism: an orchestra to be directed in cancer therapy. Pharmacological Research 131, pages 75-86.
Crossref
Crossref
Tsung-Ying Yang, Chieh-Lin Jerry Teng, Tsung-Chieh Chester Lin, Kun-Chieh Chen, Shih-Lan Hsu & Chun-Chi Wu. (2018)
Transcriptional repression of
Aurora-A
gene by wild-type p53 through directly binding to its promoter with histone deacetylase 1 and mSin3a
. International Journal of Cancer 142:1, pages 92-108.
Crossref
Crossref
Valentina Schmidt, Rachana Nagar & Luis Martinez. (2017) Control of Nucleotide Metabolism Enables Mutant p53’s Oncogenic Gain-of-Function Activity. International Journal of Molecular Sciences 18:12, pages 2759.
Crossref
Crossref
Ji-Hye Ahn, Tae Jin Kim, Jae Ho Lee & Jung-Hye Choi. (2017) Mutant p53 stimulates cell invasion through an interaction with Rad21 in human ovarian cancer cells. Scientific Reports 7:1.
Crossref
Crossref
Takehiro Ogata, Mizuyo Nakamura, Meijie Sang, Hiroyuki Yoda, Kiriko Hiraoka, Danjing Yin, Mexiang Sang, Osamu Shimozato & Toshinori Ozaki. (2017) Depletion of runt-related transcription factor 2 (RUNX2) enhances SAHA sensitivity of p53-mutated pancreatic cancer cells through the regulation of mutant p53 and TAp63. PLOS ONE 12:7, pages e0179884.
Crossref
Crossref
Maria Ferraiuolo, Lorena Verduci, Giovanni Blandino & Sabrina Strano. (2017) Mutant p53 Protein and the Hippo Transducers YAP and TAZ: A Critical Oncogenic Node in Human Cancers. International Journal of Molecular Sciences 18:5, pages 961.
Crossref
Crossref
Neil T. Pfister & Carol Prives. (2017) Transcriptional Regulation by Wild-Type and Cancer-Related Mutant Forms of p53. Cold Spring Harbor Perspectives in Medicine 7:2, pages a026054.
Crossref
Crossref
Chao He, Lun Li, Xuan Guan, Li Xiong & Xiongying Miao. (2017) Mutant p53 Gain of Function and Chemoresistance: The Role of Mutant p53 in Response to Clinical Chemotherapy. Chemotherapy 62:1, pages 43-53.
Crossref
Crossref
David Olivos & Lindsey Mayo. (2016) Emerging Non-Canonical Functions and Regulation by p53: p53 and Stemness. International Journal of Molecular Sciences 17:12, pages 1982.
Crossref
Crossref
Barbara A. Helfrich, Jihye Kim, Dexiang Gao, Daniel C. Chan, Zhiyong Zhang, Aik-Choon Tan & Paul A. BunnJrJr. (2016)
Barasertib (AZD1152), a Small Molecule Aurora B Inhibitor, Inhibits the Growth of SCLC Cell Lines
In Vitro
and
In Vivo
. Molecular Cancer Therapeutics 15:10, pages 2314-2322.
Crossref
Crossref
Marek Petr, Robert Helma, Alena Polášková, Aneta Krejčí, Zuzana Dvořáková, Iva Kejnovská, Lucie Navrátilová, Matej Adámik, Michaela Vorlíčková & Marie Brázdová. (2016)
Wild-type p53 binds to
MYC
promoter G-quadruplex
. Bioscience Reports 36:5.
Crossref
Crossref
Jessica A. Monteith, Hestia Mellert, Morgan A. Sammons, Laudita A. Kuswanto, Stephen M. Sykes, Lois Resnick-Silverman, James J. Manfredi, Shelley L. Berger & Steven B. McMahon. (2016) A rare DNA contact mutation in cancer confers p53 gain-of-function and tumor cell survival via TNFAIP8 induction. Molecular Oncology 10:8, pages 1207-1220.
Crossref
Crossref
William M Kamp, Ping-yuan Wang & Paul M Hwang. (2016) TP53 mutation, mitochondria and cancer. Current Opinion in Genetics & Development 38, pages 16-22.
Crossref
Crossref
Lydia AschauerPatricia A.J. Muller. (2016) Novel targets and interaction partners of mutant p53 Gain-Of-Function. Biochemical Society Transactions 44:2, pages 460-466.
Crossref
Crossref
Maria Ferraiuolo, Silvia Di Agostino, Giovanni Blandino & Sabrina Strano. (2016) Oncogenic Intra-p53 Family Member Interactions in Human Cancers. Frontiers in Oncology 6.
Crossref
Crossref
WEI SHEN, DANQI CHEN, SHANSHAN LIU, LISHA CHEN, AIWEN YU, HAO FU & XIUJU SUN. (2015) S100A4 interacts with mutant p53 and affects gastric cancer MKN1 cell autophagy and differentiation. International Journal of Oncology 47:6, pages 2123-2130.
Crossref
Crossref
B S Tan, K H Tiong, H L Choo, F Fei-Lei Chung, L-W Hii, S H Tan, I KS Yap, S Pani, N TW Khor, S F Wong, R Rosli, S-K Cheong & C-O Leong. (2015) Mutant p53-R273H mediates cancer cell survival and anoikis resistance through AKT-dependent suppression of BCL2-modifying factor (BMF). Cell Death & Disease 6:7, pages e1826-e1826.
Crossref
Crossref
M Subramanian, P Francis, S Bilke, X L Li, T Hara, X Lu, M F Jones, R L Walker, Y Zhu, M Pineda, C Lee, L Varanasi, Y Yang, L A Martinez, J Luo, S Ambs, S Sharma, L M Wakefield, P S Meltzer & A Lal. (2014) A mutant p53/let-7i-axis-regulated gene network drives cell migration, invasion and metastasis. Oncogene 34:9, pages 1094-1104.
Crossref
Crossref
Biswa Pratim Das Purkayastha & Jagat Kumar Roy. (2015) Cancer cell metabolism and developmental homeodomain/POU domain transcription factors: A connecting link. Cancer Letters 356:2, pages 315-319.
Crossref
Crossref
Wensheng Yan, Yong-Sam Jung, Yanhong Zhang & Xinbin Chen. (2014) Arsenic Trioxide Reactivates Proteasome-Dependent Degradation of Mutant p53 Protein in Cancer Cells in Part via Enhanced Expression of Pirh2 E3 Ligase. PLoS ONE 9:8, pages e103497.
Crossref
Crossref
Alessandra Bisio, Yari Ciribilli, Gilberto Fronza, Alberto Inga & Paola Monti. (2014) TP53 Mutants in the Tower of Babel of Cancer Progression. Human Mutation 35:6, pages 689-701.
Crossref
Crossref
YANPING CUN, NAN DAI, MENGXIA LI, CHENGJIE XIONG, QINHONG ZHANG, JIANGDONG SUI, CHENGYUAN QIAN & DONG WANG. (2014) APE1/Ref-1 enhances DNA binding activity of mutant p53 in a redox-dependent manner. Oncology Reports 31:2, pages 901-909.
Crossref
Crossref
Raffaela Santoro, Sabrina Strano & Giovanni Blandino. 2014. Mutant p53 and MDM2 in Cancer. Mutant p53 and MDM2 in Cancer
91
103
.
Anjana K. Negi, Shevali Kansal, Archana Bhatnagar & Navneet Agnihotri. (2013) Alteration in apoptosis and cell cycle by celecoxib and/or fish oil in 7,12-dimethyl benzene (α) anthracene-induced mammary carcinogenesis. Tumor Biology 34:6, pages 3753-3764.
Crossref
Crossref
SHINGO KOZONO, KENOKI OHUCHIDA, TAKAO OHTSUKA, LIN CUI, DAIKI EGUCHI, KENJI FUJIWARA, MING ZHAO, KAZUHIRO MIZUMOTO & MASAO TANAKA. (2013) S100A4 mRNA expression level is a predictor of radioresistance of pancreatic cancer cells. Oncology Reports 30:4, pages 1601-1608.
Crossref
Crossref
Pavla Brachova, Kristina Thiel & Kimberly Leslie. (2013) The Consequence of Oncomorphic TP53 Mutations in Ovarian Cancer. International Journal of Molecular Sciences 14:9, pages 19257-19275.
Crossref
Crossref
Bryant England, Tiangui Huang & Michael Karsy. (2013) Current understanding of the role and targeting of tumor suppressor p53 in glioblastoma multiforme. Tumor Biology 34:4, pages 2063-2074.
Crossref
Crossref
P Dong, M Karaayvaz, N Jia, M Kaneuchi, J Hamada, H Watari, S Sudo, J Ju & N Sakuragi. (2012) Mutant p53 gain-of-function induces epithelial–mesenchymal transition through modulation of the miR-130b–ZEB1 axis. Oncogene 32:27, pages 3286-3295.
Crossref
Crossref
Hui Jin, Lei Liang, Lifeng Liu, Weiping Deng & Jianwen Liu. (2013) HDAC inhibitor DWP0016 activates p53 transcription and acetylation to inhibit cell growth in U251 glioblastoma cells. Journal of Cellular Biochemistry 114:7, pages 1498-1509.
Crossref
Crossref
W Wang, B Cheng, L Miao, Y Mei & M Wu. (2013) Mutant p53-R273H gains new function in sustained activation of EGFR signaling via suppressing miR-27a expression. Cell Death & Disease 4:4, pages e574-e574.
Crossref
Crossref
Toshinori Ozaki, Akira Nakagawara & Hiroki Nagase. (2013) RUNX Family Participates in the Regulation of p53-Dependent DNA Damage Response. International Journal of Genomics 2013, pages 1-12.
Crossref
Crossref
William A. Freed-Pastor & Carol Prives. (2012) Mutant p53: one name, many proteins. Genes & Development 26:12, pages 1268-1286.
Crossref
Crossref
S Donzelli, G Fontemaggi, F Fazi, S Di Agostino, F Padula, F Biagioni, P Muti, S Strano & G Blandino. (2011) MicroRNA-128-2 targets the transcriptional repressor E2F5 enhancing mutant p53 gain of function. Cell Death & Differentiation 19:6, pages 1038-1048.
Crossref
Crossref
Courtney H. Coschi & Frederick A. Dick. (2012) Chromosome instability and deregulated proliferation: an unavoidable duo. Cellular and Molecular Life Sciences 69:12, pages 2009-2024.
Crossref
Crossref
Shih-Hsin Tu, Chih-Hsiung Wu, Li-Ching Chen, Ching-Shui Huang, Hui-Wen Chang, Chien-Hsi Chang, Hsiu-Man Lien & Yuan-Soon Ho. (2012)
In Vivo Antitumor Effects of 4,7-Dimethoxy-5-methyl-1,3-benzodioxole Isolated from the Fruiting Body of
Antrodia camphorata
through Activation of the p53-Mediated p27/Kip1 Signaling Pathway
. Journal of Agricultural and Food Chemistry 60:14, pages 3612-3618.
Crossref
Crossref
Razmik Mirzayans, Bonnie Andrais, April Scott & David Murray. (2012) New Insights into p53 Signaling and Cancer Cell Response to DNA Damage: Implications for Cancer Therapy. Journal of Biomedicine and Biotechnology 2012, pages 1-16.
Crossref
Crossref
Jason N. Sterrenberg, Gregory L. Blatch & Adrienne L. Edkins. (2011) Human DNAJ in cancer and stem cells. Cancer Letters 312:2, pages 129-142.
Crossref
Crossref
Wensheng Yan, Yanhong Zhang, Jin Zhang, Shou Liu, Seong Jun Cho & Xinbin Chen. (2011) Mutant p53 Protein Is Targeted by Arsenic for Degradation and Plays a Role in Arsenic-mediated Growth Suppression. Journal of Biological Chemistry 286:20, pages 17478-17486.
Crossref
Crossref
Toshinori Ozaki & Akira Nakagawara. (2011) Role of p53 in Cell Death and Human Cancers. Cancers 3:1, pages 994-1013.
Crossref
Crossref
Hsiu-Man Lien, Hsiao-Wei Lin, Ying-Jan Wang, Li-Ching Chen, Ding-Yah Yang, Ya-Yun Lai & Yuan-Soon Ho. (2011)
Inhibition of Anchorage-Independent Proliferation and G0/G1 Cell-Cycle Regulation in Human Colorectal Carcinoma Cells by 4,7-Dimethoxy-5-Methyl-l,3-Benzodioxole Isolated from the Fruiting Body of
Antrodia camphorate
. Evidence-Based Complementary and Alternative Medicine 2011, pages 1-10.
Crossref
Crossref
L Jin, Y Tabe, S Kimura, Y Zhou, J Kuroda, H Asou, T Inaba, M Konopleva, M Andreeff & T Miida. (2010) Antiproliferative and proapoptotic activity of GUT-70 mediated through potent inhibition of Hsp90 in mantle cell lymphoma. British Journal of Cancer 104:1, pages 91-100.
Crossref
Crossref
Shinji Mizuarai & Hidehito Kotani. (2010) Synthetic lethal interactions for the development of cancer therapeutics: biological and methodological advancements. Human Genetics 128:6, pages 567-575.
Crossref
Crossref
Abhijit Ghosh, Tina Chunyuan Chen & Yvonne L. Kapila. (2010) Anoikis triggers Mdm2-dependent p53 degradation. Molecular and Cellular Biochemistry 343:1-2, pages 201-209.
Crossref
Crossref
Wensheng Yan & Xinbin Chen. (2010) Characterization of Functional Domains Necessary for Mutant p53 Gain of Function. Journal of Biological Chemistry 285:19, pages 14229-14238.
Crossref
Crossref
Aymone Gurtner, Giuseppe Starace, Giuseppe Norelli, Giulia Piaggio, Ada Sacchi & Gianluca Bossi. (2010) Mutant p53-induced Up-regulation of Mitogen-activated Protein Kinase Kinase 3 Contributes to Gain of Function. Journal of Biological Chemistry 285:19, pages 14160-14169.
Crossref
Crossref
Kazuhito Yoshikawa, Jun-ichi Hamada, Mitsuhiro Tada, Takeshi Kameyama, Koji Nakagawa, Yukiko Suzuki, Mayumi Ikawa, Nur Mohammad Monsur Hassan, Yoshimasa Kitagawa & Tetsuya Moriuchi. (2010) Mutant p53 R248Q but not R248W enhances in vitro invasiveness of human lung cancer NCI-H1299 cells. Biomedical Research 31:6, pages 401-411.
Crossref
Crossref
Amy Chadburn & Ethel Cesarman. 2010. Molecular Pathology of Hematolymphoid Diseases. Molecular Pathology of Hematolymphoid Diseases
367
385
.
Tae-Hyun Kim, Sang Yull Lee, Jee Hyun Rho, Na Young Jeong, Young Hwa Soung, Wol Soon Jo, Do-Young Kang, Sung-Heun Kim & Young Hyun Yoo. (2009) Mutant p53 (G199V) Gains Antiapoptotic Function through Signal Transducer and Activator of Transcription 3 in Anaplastic Thyroid Cancer Cells. Molecular Cancer Research 7:10, pages 1645-1654.
Crossref
Crossref
Ran Brosh & Varda Rotter. (2009) When mutants gain new powers: news from the mutant p53 field. Nature Reviews Cancer 9:10, pages 701-713.
Crossref
Crossref
Yosef Buganim & Varda Rotter. (2009) p53: Balancing tumour suppression and implications for the clinic. European Journal of Cancer 45, pages 217-234.
Crossref
Crossref
Wensheng Yan & Xinbin Chen. (2009) Identification of GRO1 as a Critical Determinant for Mutant p53 Gain of Function. Journal of Biological Chemistry 284:18, pages 12178-12187.
Crossref
Crossref
Luca Lavra, Alessandra Ulivieri, Cinzia Rinaldo, Roberto Dominici, Marco Volante, Emidio Luciani, Armando Bartolazzi, Francesco Frasca, Silvia Soddu & Salvatore Sciacchitano. (2009)
Gal-3
is stimulated by gain-of-function
p53
mutations and modulates chemoresistance in anaplastic thyroid carcinomas
. The Journal of Pathology 218:1, pages 66-75.
Crossref
Crossref
Marie Brázdová, Timo Quante, Lars Tögel, Korden Walter, Christine Loscher, Vlastimil Tichý, Lenka Činčárová, Wolfgang Deppert & Genrich V. Tolstonog. (2009) Modulation of gene expression in U251 glioblastoma cells by binding of mutant p53 R273H to intronic and intergenic sequences. Nucleic Acids Research 37:5, pages 1486-1500.
Crossref
Crossref
Heping Yang, Tony W. H. Li, Kwang Suk Ko, Meng Xia & Shelly C. Lu. (2009) Switch from Mnt-Max to Myc-Max induces p53 and cyclin D1 expression and apoptosis during cholestasis in mouse and human hepatocytes. Hepatology 49:3, pages 860-870.
Crossref
Crossref
X Sui, S Shin, R Zhang, P F Firozi, L Yang, J L Abbruzzese & S A G Reddy. (2008) Hdm2 is regulated by K-Ras and mediates p53-independent functions in pancreatic cancer cells. Oncogene 28:5, pages 709-720.
Crossref
Crossref
David Reuss & Andreas von Deimling. 2009. Gliomas. Gliomas
83
102
.
Kristina Heyne, Katrin Schmitt, Daniel Mueller, Vivienne Armbruester, Pedro Mestres & Klaus Roemer. (2008) Resistance of mitochondrial p53 to dominant inhibition. Molecular Cancer 7:1.
Crossref
Crossref
Ken H. YoungKaren LeroyMichael B. MøllerGisele W. B. ColleoniMargarita Sánchez-BeatoFábio R. KerbauyCorinne HaiounJens C. EickhoffAllen H. YoungPhilippe GaulardMiguel A. PirisTerry D. OberleyWilliam M. RehrauerBrad S. KahlJames S. MalterElias CampoJan DelabieRandy D. GascoyneAndreas RosenwaldLisa RimszaJames HuangRita M. BrazielElaine S. Jaffe, Wyndham H. Wilson, Louis M. Staudt, Julie M. Vose, Wing C. Chan, Dennis D. Weisenburger & Timothy C. Greiner. (2008) Structural profiles of TP53 gene mutations predict clinical outcome in diffuse large B-cell lymphoma: an international collaborative study. Blood 112:8, pages 3088-3098.
Crossref
Crossref
Wensheng Yan, Gang Liu, Ariane Scoumanne & Xinbin Chen. (2008) Suppression of Inhibitor of Differentiation 2, a Target of Mutant p53, Is Required for Gain-of-Function Mutations. Cancer Research 68:16, pages 6789-6796.
Crossref
Crossref
Elisa Guida, Andrea Bisso, Cristina Fenollar-Ferrer, Marco Napoli, Claudio Anselmi, Javier E. Girardini, Paolo Carloni & Giannino Del Sal. (2008) Peptide Aptamers Targeting Mutant p53 Induce Apoptosis in Tumor Cells. Cancer Research 68:16, pages 6550-6558.
Crossref
Crossref
Inken Wierstra & Jürgen Alves. 2008.
113
333
.
E Kim & W Deppert. (2007) Interactions of mutant p53 with DNA: guilt by association. Oncogene 26:15, pages 2185-2190.
Crossref
Crossref
S Strano, S Dell'Orso, S Di Agostino, G Fontemaggi, A Sacchi & G Blandino. (2007) Mutant p53: an oncogenic transcription factor. Oncogene 26:15, pages 2212-2219.
Crossref
Crossref
L Weisz, M Oren & V Rotter. (2007) Transcription regulation by mutant p53. Oncogene 26:15, pages 2202-2211.
Crossref
Crossref
Galina Selivanova, Vladimir J. N. Bykov & Klas G. Wiman. 2007. 25 Years of p53 Research. 25 Years of p53 Research
399
419
.
Olimpia Monti, Alexander Damalas, Sabrina Strano & Giovanni Blandino. 2007. 25 Years of p53 Research. 25 Years of p53 Research
223
232
.
L Hui, Y Zheng, Y Yan, J Bargonetti & D A Foster. (2006) Mutant p53 in MDA-MB-231 breast cancer cells is stabilized by elevated phospholipase D activity and contributes to survival signals generated by phospholipase D. Oncogene 25:55, pages 7305-7310.
Crossref
Crossref
Shana Thomas & David Reisman. (2006) Localization of a mutant p53 response element on the Tissue Inhibitor of Metalloproteinase-3 promoter: Mutant p53 activities are distinct from wild-type. Cancer Letters 240:1, pages 48-59.
Crossref
Crossref
Manabu Matsumoto, Mutsuo Furihata & Yuji Ohtsuki. (2006) Posttranslational phosphorylation of mutant p53 protein in tumor development. Medical Molecular Morphology 39:2, pages 79-87.
Crossref
Crossref
A Zalcenstein, L Weisz, P Stambolsky, J Bar, V Rotter & M Oren. (2005) Repression of the MSP/MST-1 gene contributes to the antiapoptotic gain of function of mutant p53. Oncogene 25:3, pages 359-369.
Crossref
Crossref
G Bossi, E Lapi, S Strano, C Rinaldo, G Blandino & A Sacchi. (2005) Mutant p53 gain of function: reduction of tumor malignancy of human cancer cell lines through abrogation of mutant p53 expression. Oncogene 25:2, pages 304-309.
Crossref
Crossref
Vladislava O. Melnikova & Honnavara N. Ananthaswamy. 2006. Molecular Mechanisms of Basal Cell and Squamous Cell Carcinomas. Molecular Mechanisms of Basal Cell and Squamous Cell Carcinomas
66
79
.
Alex Sigal & Varda Rotter. 2005. The p53 Tumor Suppressor Pathway and Cancer. The p53 Tumor Suppressor Pathway and Cancer
199
223
.
Gene A. Lang, Tomoo Iwakuma, Young-Ah Suh, Geng Liu, V.Ashutosh Rao, John M. Parant, Yasmine A. Valentin-Vega, Tamara Terzian, Lisa C. Caldwell, Louise C. Strong, Adel K. El-Naggar & Guillermina Lozano. (2004) Gain of Function of a p53 Hot Spot Mutation in a Mouse Model of Li-Fraumeni Syndrome. Cell 119:6, pages 861-872.
Crossref
Crossref
Ella Kim & Wolfgang Deppert. (2004) Transcriptional activities of mutant p53: When mutations are more than a loss. Journal of Cellular Biochemistry 93:5, pages 878-886.
Crossref
Crossref
Lilach Weisz, Amir Zalcenstein, Perry Stambolsky, Yehudit Cohen, Naomi Goldfinger, Moshe Oren & Varda Rotter. (2004)
Transactivation of the
EGR1
Gene Contributes to Mutant p53 Gain of Function
. Cancer Research 64:22, pages 8318-8327.
Crossref
Crossref
Thomas J. O’Farrell, Paritosh Ghosh, Nobuaki Dobashi, Carl Y. Sasaki & Dan L. Longo. (2004) Comparison of the Effect of Mutant and Wild-Type p53 on Global Gene Expression. Cancer Research 64:22, pages 8199-8207.
Crossref
Crossref
Ann M. Bode & Zigang Dong. (2004) Post-translational modification of p53 in tumorigenesis. Nature Reviews Cancer 4:10, pages 793-805.
Crossref
Crossref
Claudia Fritzsche, Geraldine Zeller, Karl X. Knaup & Klaus Roemer. (2004) No anti-apoptotic effects of single copies of mutant p53 genes in drug-treated tumor cells. Anti-Cancer Drugs 15:7, pages 679-688.
Crossref
Crossref
K.X Knaup & K Roemer. (2004) Cell type-specific regulation of calmodulin 2 expression by mutant p53. FEBS Letters 569:1-3, pages 70-74.
Crossref
Crossref
Licio Collavin, Monica Gostissa, Fabio Avolio, Paola Secco, Antonella Ronchi, Claudio Santoro & Giannino Del Sal. (2004) Modification of the erythroid transcription factor GATA-1 by SUMO-1. Proceedings of the National Academy of Sciences 101:24, pages 8870-8875.
Crossref
Crossref
Amy Willis, Eun Joo Jung, Therese Wakefield & Xinbin Chen. (2004) Mutant p53 exerts a dominant negative effect by preventing wild-type p53 from binding to the promoter of its target genes. Oncogene 23:13, pages 2330-2338.
Crossref
Crossref
Jing Gao, Hong-Ying Huang, Joanne Pak, Jin Cheng, Zhong-Ting Zhang, Ellen Shapiro, Angel Pellicer, Tung-Tien Sun & Xue-Ru Wu. (2004) p53 deficiency provokes urothelial proliferation and synergizes with activated Ha-ras in promoting urothelial tumorigenesis. Oncogene 23:3, pages 687-696.
Crossref
Crossref
Amir Zalcenstein, Perry Stambolsky, Lilach Weisz, Martina Müller, David Wallach, Tanya M Goncharov, Peter H Krammer, Varda Rotter & Moshe Oren. (2003) Mutant p53 gain of function: repression of CD95(Fas/APO-1) gene expression by tumor-associated p53 mutants. Oncogene 22:36, pages 5667-5676.
Crossref
Crossref
Huqun, Yoshiyuki Endo, Hong Xin, Mitsu Takahashi, Toshihiro Nukiwa & Koichi Hagiwara. (2003) A naturally occurring p73 mutation in a p73-p53 double-mutant lung cancer cell line encodes p73alpha protein with a dominant-negative function. Cancer Science 94:8, pages 718-724.
Crossref
Crossref
Wenrui Duan, Haiming Ding, Mark A Subler, Wei-Guo Zhu, Huiming Zhang, Gary D Stoner, Jolene J Windle, Gregory A Otterson & Miguel A Villalona-Calero. (2002) Lung-specific expression of human mutant p53-273H is associated with a high frequency of lung adenocarcinoma in transgenic mice. Oncogene 21:51, pages 7831-7838.
Crossref
Crossref
Annemieke Atema & Patrick Chène. (2002) The gain of function of the p53 mutant Asp281Gly is dependent on its ability to form tetramers. Cancer Letters 185:1, pages 103-109.
Crossref
Crossref
Alberto Inga, Dorit Nahari, Susana Velasco-Miguel, Errol C Friedberg & Michael A Resnick. (2002) A novel p53 mutational hotspot in skin tumors from UV-irradiated Xpc mutant mice alters transactivation functions. Oncogene 21:37, pages 5704-5715.
Crossref
Crossref
Elena N Pugacheva, Alexey V Ivanov, Julia E Kravchenko, Boris P Kopnin, Arnold J Levine & Peter M Chumakov. (2002) Novel gain of function activity of p53 mutants: activation of the dUTPase gene expression leading to resistance to 5-fluorouracil. Oncogene 21:30, pages 4595-4600.
Crossref
Crossref
Sabrina Strano, Giulia Fontemaggi, Antonio Costanzo, Maria Giulia Rizzo, Olimpia Monti, Alessia Baccarini, Giannino Del Sal, Massimo Levrero, Ada Sacchi, Moshe Oren & Giovanni Blandino. (2002) Physical Interaction with Human Tumor-derived p53 Mutants Inhibits p63 Activities. Journal of Biological Chemistry 277:21, pages 18817-18826.
Crossref
Crossref
Suman Gangopadhyay, Farid Jalali, Danny Reda, Jim Peacock, Robert G. Bristow & Samuel Benchimol. (2002) Expression of Different Mutant p53 Transgenes in Neuroblastoma Cells Leads to Different Cellular Responses to Genotoxic Agents. Experimental Cell Research 275:1, pages 122-131.
Crossref
Crossref
Yvonne L. Kapila, Shaohui Wang, Paul Dazin, Elizabeth Tafolla & Marc J. Mass. (2002) The Heparin-binding Domain and V Region of Fibronectin Regulate Apoptosis by Suppression of p53 and c-myc in Human Primary Cells. Journal of Biological Chemistry 277:10, pages 8482-8491.
Crossref
Crossref
Ang YuanChong-Jen YuKwen-Tay LuhSow-Hsong KuoYung-Chie LeePan-Chyr Yang. (2002)
Aberrant
p53
Expression Correlates With Expression of Vascular Endothelial Growth Factor mRNA and Interleukin-8 mRNA and Neoangiogenesis in Non–Small-Cell Lung Cancer
. Journal of Clinical Oncology 20:4, pages 900-910.
Crossref
Crossref
Debabrita Deb, Mariano Scian, Katherine E Roth, Wei Li, Jane Keiger, Abhay Sankar Chakraborti, Swati Palit Deb & Sumitra Deb. (2002) Hetero-oligomerization does not compromise ‘gain of function’ of tumor-derived p53 mutants. Oncogene 21:2, pages 176-189.
Crossref
Crossref
Ken Yagi, Masao Furuhashi, Hiromasa Aoki, Daisuke Goto, Hiroyuki Kuwano, Kazuo Sugamura, Kohei Miyazono & Mitsuyasu Kato. (2002) c-myc Is a Downstream Target of the Smad Pathway. Journal of Biological Chemistry 277:1, pages 854-861.
Crossref
Crossref
Shirley A. Albano, Ernesto Santana-Sahagun & Michael H. Weisman. (2001) Cigarette smoking and rheumatoid arthritis. Seminars in Arthritis and Rheumatism 31:3, pages 146-159.
Crossref
Crossref
Yanhua Peng, Lihong Chen, Changgong Li, Wenge Lu & Jiandong Chen. (2001) Inhibition of MDM2 by hsp90 Contributes to Mutant p53 Stabilization. Journal of Biological Chemistry 276:44, pages 40583-40590.
Crossref
Crossref
Janardhan Sampath, Daxi Sun, Vincent J. Kidd, Jose Grenet, Amisha Gandhi, Linda H. Shapiro, Qingjian Wang, Gerard P. Zambetti & John D. Schuetz. (2001) Mutant p53 Cooperates with ETS and Selectively Up-regulates Human MDR1 Not MRP1. Journal of Biological Chemistry 276:42, pages 39359-39367.
Crossref
Crossref
Craig Cadwell & Gerard P Zambetti. (2001) The effects of wild-type p53 tumor suppressor activity and mutant p53 gain-of-function on cell growth. Gene 277:1-2, pages 15-30.
Crossref
Crossref
Alex Sigal, Devorah Matas, Nava Almog, Naomi Goldfinger & Varda Rotter. (2001) The C-terminus of mutant p53 is necessary for its ability to interfere with growth arrest or apoptosis. Oncogene 20:35, pages 4891-4898.
Crossref
Crossref
Raul C. RibeiroFabiano SandriniBonald FigueiredoGerard P. ZambettiEdson MichalkiewiczAntony R. LaffertyLuiz DeLacerdaMark RabinCraig CadwellGilberto SampaioIsrail CatConstantine A. StratakisRomolo Sandrini. (2001)
An inherited
p53
mutation that contributes in a tissue-specific manner to pediatric adrenal cortical carcinoma
. Proceedings of the National Academy of Sciences 98:16, pages 9330-9335.
Crossref
Crossref
Alberto Inga & Michael A Resnick. (2001) Novel human p53 mutations that are toxic to yeast can enhance transactivation of specific promoters and reactivate tumor p53 mutants. Oncogene 20:26, pages 3409-3419.
Crossref
Crossref
Mariam Grigorian, Susanne Andresen, Eugene Tulchinsky, Marina Kriajevska, Charlotte Carlberg, Charlotte Kruse, Martin Cohn, Noona Ambartsumian, Annette Christensen, Galina Selivanova & Eugene Lukanidin. (2001) Tumor Suppressor p53 Protein Is a New Target for the Metastasis-associated Mts1/S100A4 Protein. Journal of Biological Chemistry 276:25, pages 22699-22708.
Crossref
Crossref
Patrick Chène. (2001) The role of tetramerization in p53 function. Oncogene 20:21, pages 2611-2617.
Crossref
Crossref
V. A. Kordyum. (2001) Problem of tumor origin as it is from the molecular genetics point of view. Biopolymers and Cell 17:2, pages 109-139.
Crossref
Crossref
Yanhua Peng, Lihong Chen, Changgong Li, Wenge Lu, Sudhir Agrawal & Jiandong Chen. (2001) Stabilization of the MDM2 Oncoprotein by Mutant p53. Journal of Biological Chemistry 276:9, pages 6874-6878.
Crossref
Crossref
Sabrina Strano, Mario Rossi, Giulia Fontemaggi, Eliana Munarriz, Silvia Soddu, Ada Sacchi & Giovanni Blandino. (2001) From p63 to p53 across p73. FEBS Letters 490:3, pages 163-170.
Crossref
Crossref
Cynthia C. Wetzel & Steven J. Berberich. (2001) p53 binds to cisplatin-damaged DNA. Biochimica et Biophysica Acta (BBA) - Gene Structure and Expression 1517:3, pages 392-397.
Crossref
Crossref
Juhong Liu, Sasha Akoulitchev, Achim Weber, Hui Ge, Sergei Chuikov, Daniel Libutti, Xin W Wang, Joan Weliky Conaway, Curtis C Harris, Ronald C Conaway, Danny Reinberg & David Levens. (2001) Defective Interplay of Activators and Repressors with TFIIH in Xeroderma Pigmentosum. Cell 104:3, pages 353-363.
Crossref
Crossref
Alberto Inga, Paola Monti, Gilberto Fronza, Tom Darden & Michael A Resnick. (2001) p53 mutants exhibiting enhanced transcriptional activation and altered promoter selectivity are revealed using a sensitive, yeast-based functional assay. Oncogene 20:4, pages 501-513.
Crossref
Crossref
Kristen L. Murphey & Jeffrey M. Rosen. 2001. Hormonal Carcinogenesis III. Hormonal Carcinogenesis III
189
197
.
Agustin Chicas, Patricia Molina & Jill Bargonetti. (2000) Mutant p53 Forms a Complex with Sp1 on HIV-LTR DNA. Biochemical and Biophysical Research Communications 279:2, pages 383-390.
Crossref
Crossref
Sabrina Strano, Eliana Munarriz, Mario Rossi, Barbara Cristofanelli, Yosef Shaul, Luisa Castagnoli, Arnold J. Levine, Ada Sacchi, Gianni Cesareni, Moshe Oren & Giovanni Blandino. (2000) Physical and Functional Interaction between p53 Mutants and Different Isoforms of p73. Journal of Biological Chemistry 275:38, pages 29503-29512.
Crossref
Crossref
Yi Pan & Dale S Haines. (2000) Identification of a tumor-derived p53 mutant with novel transactivating selectivity. Oncogene 19:27, pages 3095-3100.
Crossref
Crossref
Eva Ceballos, M Dolores Delgado, Pilar Gutierrez, Carlos Richard, Daniel Müller, Martin Eilers, Mats Ehinger, Urban Gullberg & Javier León. (2000) c-Myc antagonizes the effect of p53 on apoptosis and p21WAF1 transactivation in K562 leukemia cells. Oncogene 19:18, pages 2194-2204.
Crossref
Crossref
Yubo Sun, Jamie M. Cheung, Joanne Martel-Pelletier, Jean P. Pelletier, Leonor Wenger, Roy D. Altman, David S. Howell & Herman S. Cheung. (2000) Wild Type and Mutant p53 Differentially Regulate the Gene Expression of Human Collagenase-3 (hMMP-13). Journal of Biological Chemistry 275:15, pages 11327-11332.
Crossref
Crossref
Kristen L Murphy & Jeffrey M Rosen. (2000) Mutant p53 and genomic instability in a transgenic mouse model of breast cancer. Oncogene 19:8, pages 1045-1051.
Crossref
Crossref
Mingjia Tan, Yixin Wang, Kunliang Guan & Yi Sun. (2000)
PTGF-β
, a type β transforming growth factor (TGF-β) superfamily member, is a p53 target gene that inhibits tumor cell growth via TGF-β signaling pathway
. Proceedings of the National Academy of Sciences 97:1, pages 109-114.
Crossref
Crossref
W Troy Loging & David Reisman. (1999) Inhibition of the putative tumor suppressor gene TIMP-3 by tumor-derived p53 mutants and wild type p53. Oncogene 18:52, pages 7608-7615.
Crossref
Crossref
Xiaolong Yang, Alan Pater & Shou-Ching Tang. (1999) Cloning and characterization of the human BAG-1 gene promoter: upregulation by tumor-derived p53 mutants. Oncogene 18:32, pages 4546-4553.
Crossref
Crossref
Hans-Christoph Kirch, Susanne Flaswinkel, Heike Rumpf, Dieter Brockmann & Helmut Esche. (1999) Expression of human p53 requires synergistic activation of transcription from the p53 promoter by AP-1, NF-κB and Myc/Max. Oncogene 18:17, pages 2728-2738.
Crossref
Crossref
Patrick Chène & Elisabeth Bechter. (1999) P53 mutants without a functional tetramerisation domain are not oncogenic 1 1Edited by A. R. Fersht. Journal of Molecular Biology 286:5, pages 1269-1274.
Crossref
Crossref
Giovanni Blandino, Arnold J Levine & Moshe Oren. (1999) Mutant p53 gain of function: differential effects of different p53 mutants on resistance of cultured cells to chemotherapy. Oncogene 18:2, pages 477-485.
Crossref
Crossref
K. Roemer. (1999) Mutant p53: Gain-of-Function Oncoproteins and Wild-Type p53 Inactivators. Biological Chemistry 380:7-8.
Crossref
Crossref
XinDe Song, Hilary M. Sheppard, Anthony W. Norman & Xuan Liu. (1999) Mitogen-activated Protein Kinase Is Involved in the Degradation of p53 Protein in the Bryostatin-1-induced Differentiation of the Acute Promyelocytic Leukemia NB4 Cell Line. Journal of Biological Chemistry 274:3, pages 1677-1682.
Crossref
Crossref
Craig Cadwell & Gerard P. Zambetti. (1998) Regulators and mediators of the p53 tumor suppressor. Journal of Cellular Biochemistry 72:S30-31, pages 43-49.
Crossref
Crossref